A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects

Insulin resistance is a major pathophysiological feature in the development of type 2 diabetes (T2DM). Ferulic acid is known for attenuating the insulin resistance and reducing the blood glucose in T2DM rats. In this work, we designed and synthesized a library of new ferulic acid amides (FAA), which could be considered as ring opening derivatives of the antidiabetic PPARγ agonists Thiazolidinediones (TZDs). However, since these compounds displayed weak PPAR transactivation capacity, we employed a proteomics approach to unravel their molecular target(s) and identified the peroxiredoxin 1 (PRDX1) as a direct binding target of FAAs. Interestingly, PRDX1, a protein with antioxidant and chaperone activity, has been implied in the development of T2DM by inducing hepatic insulin resistance. SPR, mass spectrometry‐based studies, docking experiments and in vitro inhibition assay confirmed that compounds VIe and VIf bound PRDX1 and induced a dose‐dependent inhibition. Furthermore, VIe and VIf significantly improved hyperglycemia and hyperlipidemia in streptozotocin‐nicotinamide (STZ‐NA)‐induced diabetic rats as confirmed by histopathological examinations. These results provide guidance for developing the current FAAs as new potential antidiabetic agents.

[1]  Katarzyna A. Broniowska,et al.  Peroxiredoxin 1 plays a primary role in protecting pancreatic ß-cells from hydrogen peroxide and peroxynitrite. , 2020, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  D. Estrin,et al.  Catalysis of Peroxide Reduction by Fast Reacting Protein Thiols. , 2019, Chemical reviews.

[3]  Hongyu Zhou,et al.  Parvifoline AA Promotes Susceptibility of Hepatocarcinoma to Natural Killer Cell-Mediated Cytolysis by Targeting Peroxiredoxin. , 2019, Cell chemical biology.

[4]  Claudio Vinegoni,et al.  The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells , 2018, Scientific Reports.

[5]  Grant Lythe,et al.  First passage events in biological systems with non-exponential inter-event times , 2018, Scientific Reports.

[6]  Yu Ke,et al.  Pro-Apoptotic Effects of JDA-202, a Novel Natural Diterpenoid, on Esophageal Cancer Through Targeting Peroxiredoxin I. , 2017, Antioxidants & redox signaling.

[7]  E. Novellino,et al.  A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability , 2017, Scientific Reports.

[8]  T. Tuccinardi,et al.  Drug Affinity Responsive Target Stability (DARTS) Identifies Laurifolioside as a New Clathrin Heavy Chain Modulator. , 2016, Journal of natural products.

[9]  Hongwei Ma,et al.  SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. , 2016, Cancer research.

[10]  A. Di Pizio,et al.  Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity , 2016, Journal of enzyme inhibition and medicinal chemistry.

[11]  Thikryat Neamatallah,et al.  Ferulic acid, a natural polyphenol, alleviates insulin resistance and hypertension in fructose fed rats: Effect on endothelial-dependent relaxation. , 2016, Chemico-biological interactions.

[12]  M. Gómez-Lechón,et al.  Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening , 2016, Archives of Toxicology.

[13]  J. Hong,et al.  Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases , 2016, Pharmacology & Therapeutics.

[14]  Mohamed A Helal,et al.  Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists. , 2016, European journal of medicinal chemistry.

[15]  B. N. Sinha,et al.  Monoamine Oxidase Inhibitory Activity of Ferulic Acid Amides: Curcumin‐Based Design and Synthesis , 2016, Archiv der Pharmazie.

[16]  M. Huang,et al.  Identification of H7 as a novel peroxiredoxin I inhibitor to induce differentiation of leukemia cells , 2015, Oncotarget.

[17]  D. Nowis,et al.  Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma , 2015, Oncotarget.

[18]  Yun M. Zhao,et al.  PRDX1 is involved in palmitate induced insulin resistance via regulating the activity of p38MAPK in HepG2 cells. , 2015, Biochemical and biophysical research communications.

[19]  P. Karplus,et al.  Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling. , 2015, Trends in biochemical sciences.

[20]  Olivier Sperandio,et al.  FAF-Drugs3: a web server for compound property calculation and chemical library design , 2015, Nucleic Acids Res..

[21]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[22]  A. Al-Masri,et al.  Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus , 2015, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[23]  E. Bjornsson.  Drug-induced liver injury: an overview over the most critical compounds , 2015 .

[24]  P. Alam,et al.  Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression. , 2014, Bioorganic & medicinal chemistry letters.

[25]  C. Mancuso,et al.  Ferulic acid: pharmacological and toxicological aspects. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[26]  R. Leslie,et al.  Personalizing guidelines for diabetes management: twilight or dawn of the expert? , 2013, BMC Medicine.

[27]  M. Doble,et al.  Synergistic interaction of ferulic acid with commercial hypoglycemic drugs in streptozotocin induced diabetic rats. , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[28]  Yaxue Zhao,et al.  Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. , 2012, Nature chemical biology.

[29]  S. Hemalatha,et al.  An overview on antidiabetic medicinal plants having insulin mimetic property. , 2012, Asian Pacific journal of tropical biomedicine.

[30]  A. Paradiso,et al.  Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. , 2012, Journal of medicinal chemistry.

[31]  E. Gregoraszczuk,et al.  Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line , 2012, Pharmacological reports : PR.

[32]  E. Banoglu,et al.  Synthesis, antioxidant and antimicrobial evaluation of simple aromatic esters of ferulic acid , 2011, Archives of pharmacal research.

[33]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[34]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS). , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Lowther,et al.  Protein Engineering of the Quaternary Sulfiredoxin·Peroxiredoxin Enzyme·Substrate Complex Reveals the Molecular Basis for Cysteine Sulfinic Acid Phosphorylation* , 2009, The Journal of Biological Chemistry.

[36]  V. Go,et al.  Hypoglycemic herbs and their action mechanisms , 2009, Chinese medicine.

[37]  Haibing Li,et al.  Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines. , 2008, Bioorganic & medicinal chemistry letters.

[38]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[39]  W. Lowther,et al.  Structure of the sulphiredoxin–peroxiredoxin complex reveals an essential repair embrace , 2008, Nature.

[40]  M. Engelstein,et al.  Automation of Cell-Based and Noncell-Based Permeability Assays , 2007 .

[41]  V. Menon,et al.  Ferulic Acid: Therapeutic Potential Through Its Antioxidant Property , 2007, Journal of clinical biochemistry and nutrition.

[42]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[43]  Fulvio Loiodice,et al.  Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. , 2005, Journal of medicinal chemistry.

[44]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[45]  S. Marqusee,et al.  Pulse proteolysis: A simple method for quantitative determination of protein stability and ligand binding , 2005, Nature Methods.

[46]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[47]  V. Menon,et al.  Ferulic acid alleviates lipid peroxidation in diabetic rats , 2004, Phytotherapy research : PTR.

[48]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[49]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[50]  T. Tsuno,et al.  Synthesis of amide compounds of ferulic acid, and their stimulatory effects on insulin secretion in vitro. , 2003, Bioorganic & medicinal chemistry.

[51]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[52]  L. Madsen,et al.  Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. , 1999, Journal of lipid research.

[53]  T. Hakoshima,et al.  Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  N. Altan,et al.  Effect of the sulfonylurea glyburide on superoxide dismutase in streptozotocin-induced diabetic rat muscle. , 1997, General pharmacology.

[55]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[56]  F. Yoshimura,et al.  Variation in enzymatic transient gene expression assays. , 1989, Analytical biochemistry.

[57]  B. Zak,et al.  A peroxidase-coupled method for the colorimetric determination of serum triglycerides. , 1983, Clinical chemistry.

[58]  M. Steffes,et al.  The kidney in diabetes. , 1981, The American journal of medicine.

[59]  T. Grove.  Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium. , 1979, Clinical chemistry.

[60]  E. Bernt,et al.  Enzymatic determination of total cholesterol in serum. , 1974, Zeitschrift fur klinische Chemie und klinische Biochemie.

[61]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[62]  D. Drabkin,et al.  SPECTROPHOTOMETRIC STUDIES: SPECTROPHOTOMETRIC CONSTANT FOR COMMON HAEMOGLOBIN DERIVATIVES IN HUMAN, DOG AND RABBIT BLOOD , 1932 .

[63]  A. Al-Masri,et al.  Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus. , 2014, European review for medical and pharmacological sciences.

[64]  T. Tsuno,et al.  Antioxidant activity and hypoglycemic effect of ferulic acid in STZ‐induced diabetic mice and KK‐Ay mice , 2004, BioFactors.

[65]  Millard H. Lambert,et al.  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE , 2001 .